COCP READ THE FULL COCP RESEARCH REPORT Business Update Norovirus Challenge Study to Commence in 4Q25 Cocrystal Pharma, Inc. ...

“The absence of any approved norovirus treatments or vaccines creates a substantial market opportunity for Cocrystal,” said James Martin, Cocrystal's CFO and co-CEO. “ With 685 million global cases ...

Preparations are underway for a Phase 1b norovirus challenge study to evaluate our potent, oral antiviral candidate CDI-988 as a prophylaxis and ...

Musclemecca.com, a premier online destination for bodybuilding and fitness enthusiasts, has announced the release of a ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into ...